Sangamo Therapeutics, Inc.

Yufan Biotechnologies | September 17, 2020

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

AVM Biotechnology | July 09, 2020

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

MedTech

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Cell and Gene Therapy

Aeglea BioTherapeutics, Inc. | August 25, 2022

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria. The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date. The Company also plans to r...